Inhibikase Therapeutics, Inc. (IKT) Institutional Ownership

Ownership Summary

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has 103 institutional investors that have filed 13F reports for the period ending March 2026.

• Their combined ownership stood at 66.2% of outstanding shares in March 2026, down from 117.0% in December 2025.
• Their total shares held in IKT increased 5.27% quarter over quarter, and separately, investors owning Inhibikase Therapeutics increased 114.58% from a year ago.
• Among the 103 funds, 75 bought more Inhibikase Therapeutics shares, 15 sold down, and 13 held their ground.
• Institutional investors collectively held 113.99Mn shares in Inhibikase Therapeutics as of March 2026, up by 5.71Mn shares quarter on quarter, and up 56.07Mn shares year over year.
• Sands Capital Alternatives, LLC leads ownership in IKT with 13.02Mn shares as of March 31, 2026, equal to 7.56% of outstanding shares.
• The largest buyers of Inhibikase Therapeutics for the quarter ending March 2026 were VANGUARD CAPITAL MANAGEMENT LLC (4.45Mn), BlackRock, Inc. (3.0Mn), MILLENNIUM MANAGEMENT LLC (2.76Mn), Trails Edge Capital Partners, LP (1.88Mn), SummitTX Capital, L.P. (1.52Mn).
• Leading sellers of Inhibikase Therapeutics shares for the quarter ending March 2026 were ADAR1 Capital Management, LLC (9.52Mn), PERCEPTIVE ADVISORS LLC (3.11Mn), Stonepine Capital Management, LLC (1.39Mn), Nantahala Capital Management, LLC (1.23Mn), Seven Fleet Capital Management LP (741.7K).
• Inhibikase Therapeutics's 10 largest shareholders as of March 2026 include Sands Capital Alternatives, LLC (13.02Mn), Soleus Capital Management, L.P. (10.88Mn), Fairmount Funds Management LLC (8.62Mn), Trails Edge Capital Partners, LP (8.06Mn), ADAR1 Capital Management, LLC (6.61Mn), BlackRock, Inc. (6.3Mn), Blackstone Inc. (5.94Mn), Siren, L.L.C. (5.85Mn), Commodore Capital LP (5.4Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.45Mn) per Business Quant data.